Blog
RSS FeedPosted by Michael Wonder on 25 Nov 2020
Merck racks up another NICE recommendation for Keytruda
25 November 2020 - That makes it number 12. ...
Posted by Michael Wonder on 25 Nov 2020
NICE publishes final guidance on Nubeqa
25 November 2020 - NICE has completed its assessment of darolutamide for use in combination with androgen deprivation therapy for ...
Posted by Michael Wonder on 24 Nov 2020
NICE backs Braftovi for BRAF positive colorectal cancer
24 November 2020 - NICE has back Pierre Fabre’s Braftovi plus cetuximab for the treatment of BRAF positive metastatic colorectal ...
Posted by Michael Wonder on 24 Nov 2020
New option for people with difficult-to-treat multiple myeloma is recommended for use in Cancer Drugs Fund by NICE
24 November 2020 - Around 5,700 cases of multiple myeloma are diagnosed each year in the UK. ...
Posted by Michael Wonder on 18 Nov 2020
NICE backs Lilly’s Emgality for migraine, adding pressure on Novartis
18 November 2020 - UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the ...
Posted by Michael Wonder on 12 Nov 2020
NICE recommends innovative treatment for severe blood disorder for NHS use
12 November 2020 - Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura. ...
Posted by Michael Wonder on 11 Nov 2020
NICE publishes draft guidance on new treatment for patients with immune thrombocytopenia
11 November 2020 - The Department of Health and Social Care has asked NICE to produce guidance on using fostamatinib in ...
Posted by Michael Wonder on 10 Nov 2020
NICE recommends new chemotherapy free treatment option for people with untreated chronic lymphocytic leukaemia
10 November 2020 - More than 1,000 people each year will benefit from NICE's recommendation. ...
Posted by Michael Wonder on 09 Nov 2020
NICE issues positive Final Appraisal Determination for AbbVie’s Rinvoq (upadacitinib) in severe active rheumatoid arthritis
6 November 2020 - Positive recommendation means upadacitinib will be available to those with previously treated severe active rheumatoid arthritis. ...
Posted by Michael Wonder on 08 Nov 2020
Midostaurin for treating advanced systemic mastocytosis
6 November 2020 - The Department of Health and Social Care has asked NICE to produce guidance on using midostaurin in ...
Posted by Michael Wonder on 05 Nov 2020
Skin cancer drug not cost effective for routine NHS use
5 November 2020 - A consultation on the draft recommendations has now begun until Tuesday 24 November 2020. ...
Posted by Michael Wonder on 30 Oct 2020
NICE recommends new treatment option for adults with obesity and non-diabetic hyperglycaemia who have a high risk of cardiovascular disease
30 October 2020 - All eligibility criteria must be met for liraglutide to be offered. ...
Posted by Michael Wonder on 26 Oct 2020
ICR urges change as NICE rejects Keytruda plus chemotherapy
23 October 2020 - The Institute for Cancer Research has called for change in the way immunotherapy drugs are researched ...
Posted by Michael Wonder on 26 Oct 2020
NICE recommends Bayer’s Nubeqa (darolutamide), a new treatment option for non-metastatic castration-resistant prostate cancer
23 October 2020 - Positive recommendation based on Phase 3 ARAMIS trial data in which darolutamide plus androgen deprivation therapy showed ...
Posted by Michael Wonder on 21 Oct 2020
NICE in favour of another highly specialised technology
21 October 2020 - Familial chylomicronaemia syndrome is a rare and potentially life-threatening condition that has a significant effect on the ...